Shots:

• GSK will make equity investment to gain access to Vir’s technology of $250M- priced at $37.73 (a 10% premium to closing share price on March 27- 2020). The equity investment and collaboration will complete at the same time & are conditional upon customary conditions including regulatory review by appropriate regulatory agencies under Hart-Scott-Rodino Act
• The collaboration will focus on development of specific antibody candidates identified by Vir’s platforms (VIR-7831 and VIR-7832) which demonstrated high affinity for SARS-CoV-2 spike protein and highly potent in neutralising SARS-CoV-2 in live virus-cellular assays. The companies plan to proceed directly into P-II clinical trial within next 3 to 5 mos.
• Vir’s antibody platform has been used to identify and develop antibodies for pathogens including Ebola (mAb114- currently in use in the Democratic Republic of Congo)- hepatitis B virus- influenza A- SARS-CoV-2- malaria- and others

  Ref: GSK | Image: BGR